KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

J Crown, D Stroyakovskii, D A Yardley, C-S Huang, P A Fasching, A Bardia, S Chia, S-A Im, M Martin, B Xu, C H Barrios, M Untch, R Moroose, S A Hurvitz, G N Hortobagyi, D J Slamon, F Visco, G Spera, J P Zarate, D Halligan, Z Li, S Loi

ESMO Open 10(11) 105858

PMID41320342
PMCIDPMC12684762
DOI10.1016/j.esmoop.2025.105858
发表日期2025-11-30
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: At the primary efficacy analysis of the NATALEE phase III trial, ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) demonstrated a statistically significant improvement in invasive disease-free survival (iDFS) versus NSAI alone in patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC). Continued follow-up of efficacy outcomes is important in assessing the durability of treatment benefit. We report 5-year estimates of efficacy outcomes, including an udpated analysis of overall survival (OS). PATIENTS AND METHODS: Eligible patients included pre/postmenopausal women and men with HR-positive/HER2-negative EBC and anatomic stage IIA (N1 or N0 with high-risk factors), IIB, or III disease. Patients were randomized 1 : 1 to ribociclib 400 mg/day (3 weeks on/1 week off for 3 years) + NSAI (letrozole 2.5 mg/day or anastrozole 1 mg/day for 5 years) or NSAI alone. Premenopausal women and men received goserelin. The primary endpoint was iDFS, and secondary/exploratory endpoints included distant disease-free survival, recurrence-free survival, distant recurrence-free survival, and OS. RESULTS: With a median iDFS follow-up of 55.4 months, ribociclib + NSAI demonstrated persistent iDFS benefit versus NSAI alone [hazard ratio 0.716, 95% confidence interval (CI) 0.618-0.829, nominal one-sided log-rank P < 0.0001]. Absolute iDFS improvement between treatment arms increased from the 3- (Δ2.7%) to the 5-year (Δ4.5%) time points. Persistent benefit over time was also observed across subgroups [including N0 patients (hazard ratio 0.606, 95% CI 0.372-0.986)] and secondary/exploratory endpoints. As OS continues to mature, numerical improvement in favor of ribociclib was observed (hazard ratio 0.800, 95% CI 0.637-1.003, nominal one-sided log-rank P = 0.026). CONCLUSIONS: This prespecified 5-year follow-up of efficacy outcomes from NATALEE demonstrated that ribociclib + NSAI continued to reduce the risk of recurrence beyond the 3-year treatment window, supporting its use as adjuvant therapy in patients with HR-positive/HER2-negative EBC. An ongoing positive trend for improved OS in favor of ribociclib + NSAI was observed.

KM 提取结果

3 个 Figure · 5 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2 Kaplan–Meier survival curve of iDFS in the ITT population. CI, confidence interval; IDFS, invasive disease-free survival; ITT, intention to treat; NSAI, nonsteroidal aromatase inhibitor; RIB, ribociclib. a The difference between percentages does not equal 2.7 due to rounding.

iDFS

invasive disease-free survival

Figure 2 · Panel iDFS

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel iDFS 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure3 个面板

Figure 4

Figure 4 Kaplan-Meier survival curves. Kaplan–Meier survival curves of DDFS (A), DRFS (B), and RFS (C) in the ITT population. CI, confidence interval; DDFS, distant disease-free survival; DRFS, distant recurrence-free survival; ITT, intention to treat; NSAI, nonsteroidal aromatase inhibitor; RIB, ribociclib; RFS, recurrence-free survival.

A

Distant disease-free survival

Figure 4 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Distant recurrence-free survival

Figure 4 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

Recurrence-free survival

Figure 4 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Figure 5

Figure 5 Kaplan–Meier survival curve of OS in the ITT population. CI, confidence interval; ITT, intention to treat; NSAI, nonsteroidal aromatase inhibitor; OS, overall survival; RIB, ribociclib.

Figure_5_Kaplan_Meier_survival_curve_of_OS_in_the_ITT_population.

Overall survival

Figure 5 · Panel Figure_5_Kaplan_Meier_survival_curve_of_OS_in_the_ITT_population.

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Figure_5_Kaplan_Meier_survival_curve_of_OS_in_the_ITT_population. 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 2:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Patient disposition. NSAI, nonsteroidal aromatase inhibitor; RIB, ribociclib. a Total count includes two patients randomized to the NSAI-alone arm who were given one dose each of ribociclib in error. They are accounted for in the RIB discontinuation box as ‘protocol deviation’ and ‘other’. b Patients were required to discontinue ribociclib treatment if ribociclib dosing was interrupted for >28 days due to ribociclib-related adverse events. c The NATALEE protocol required patients who discontinued NSAI treatment to also discontinue ribociclib treatment (if on ribociclib treatment). Patients who discontinued RIB treatment early could continue to receive their NSAI treatment.
非 KM Figure
Figure 3Figure 3 Subgroup analysis of iDFS. AJCC, American Joint Committee on Cancer; CI, confidence interval; CT, chemotherapy; ET, endocrine therapy; iDFS, invasive disease-free survival; ITT, intent to treat; N, node; NSAI, nonsteroidal aromatase inhibitor; RIB, ribociclib. a Includes neoadjuvant and adjuvant chemotherapy. b Nodal status classification according to AJCC staging. Nodal status is from the most advanced stage derived per surgical specimen or at diagnosis. c From archival tumor tissue.
非 KM Figure